Papers - MONZEN SATORU
-
Urinary 8-OHdG and MDA as rapid biodosimetry markers in the lethal/sublethal dose range
Monzen S, Terada K, Tawata Y, Sato T, Kousaka N, Mariya Y.
Mol Med Rep - In press 2026.3
-
Urinary metabolomic signatures associated with early adverse events during volumetric modulated arc therapy for prostate cancer: A secondary analysis of a public dataset
Fukushi M, Tatara Y, Obara H, Monzen S.
Mol Clin Oncol - In Press 2026.2
-
Fatty acid-induced lipid accumulation promotes radiosensitization in Huh7 hepatocellular carcinoma cells.
Tanaka H, Mariya Y, Monzen S
Oncology letters 31 ( 4 ) 134 2026.2
-
A multilayer biomarker strategy for Radium-223 internal radiotherapy in bone-metastatic cancer
Monzen S, Tatara Y, Fukushi Y, Kotani A, Wojcik A, Mariya Y
Precision Medicine 9 ( 1 ) 76 - 78 2026.1
-
European-Style International Training in Particle Therapy: Report on Participation in The Pianoforte Intensive Course 2025
Kotani A, Monzen S
Journal of Health Science Research - In Press 2025.12
-
Relationship between amino acid transporter activity and radioactive iodine therapy efficacy in differentiated thyroid cancer
Kotani A., Tatara Y., Sakamoto R., Wojcik A., Mariya Y., Monzen S.
Oncology Reports in press ( 6 ) 160 2025.12
-
Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) as a Biomarker for Radiation Dosimetry and Health Risk Assessment: A Review
Moloudi K, Sangsuwan T, Monzen S, Fujishima Y, Anderson D, Frey B, Miura T, Azariasl S, Yasuda H, Haghdoost S
Antioxidants 14 ( 12 ) 1393 - 1393 2025.11
-
Report on the 67th Annual Meeting of Japanese Radiation Research Society
Yamanaka T, Monzen S
Journal of Health Science Research 16 ( 1 ) 35 - 39 2025.10
-
Secretion of specific metabolites and changes in miRNA expression in murine osteoblastic cells exposed in vitro to α‑radiation.
Monzen S, Tatara Y, Chiba M, Mariya Y, Wojcik A
International journal of molecular medicine 56 ( 4 ) 161 2025.10
-
Relationship between specific microRNA expression and radioresistant conditions in HL60 acute myeloid leukemia cells.
Sugiyama H, Kikuchi M, Chiba M, Hosokawa Y, Monzen S
Molecular medicine reports 32 ( 4 ) 2025.10
-
The report of training course for molecular, cellular and tissue reactions by proton beams -PIANOFORTE Intensive Course 2024-
Yamamoto K, Chiba M, Monzen S
Journal of Health Science Research 15 ( 2 ) 37 - 44 2025.4
-
Effects of high and low LET ionizing radiation on cells ～CELET course 2024 training report～
Sato R, Fukushi M, Monzen S
Journal of Health Science Research 15 ( 2 ) 45 - 50 2025.4
-
Predicting bone marrow suppression from urinal 8-hydroxy-2'-deoxyguanosine level during the treatment with radium-223 in patients with cancer bone metastasis
Monzen S, Kasai Y, Kinbara R, Suto K, Morino Y, Terada K, Wojcik A, Mariya Y
Transl Cancer Res 14 ( 3 ) 1753 - 1763 2025.3
-
Establishment of radioresistant lung cancer cell lines and changes in gene expression
Mitsuru Chiba, Satoru Monzen
CANCER SCIENCE 116 1764 - 1764 2025.1
-
The predictive biomarker of therapeutic effect, Phospholipids, for bone metastasis from prostate cancer
Monzen, S; Kikuchi, M; Wojcik, A; Sato, R; Tanaka, H; Honda, K; Fukushi, M; Yamanaka, T; Chiba, M; Sugiyama, H; Mariya, Y
116 1762 - 1762 2025.1
-
Characteristics of sphingomyelin metabolism in the MCF7 and BT474 radiotherapy‑resistant HER2‑positive breast cancer cell lines.
Kikuchi M, Monzen S, Horikoshi M, Tsuda S, Tatara Y, Wojcik A, Mariya Y
Oncol lett 28 ( 4 ) 471 - 471 2024.10
-
Predictive lipid biomarkers in serum for therapeutic resistance of breast cancer patient under the postoperative adjuvant therapy
Monzen S, Tatara Y, Kikuchi M et al.
The Cell 56 ( 10 ) 71 - 74 2024.9
-
Exploring predictive molecules of acute adverse events in response to volumetric‑modulated arc therapy for prostate cancer using urinary metabolites.
Obara H, Tatara Y, Monzen S, Murakami S, Yamamoto H, Kimura N, Suzuki M, Komai F, Narita M, Hatayama Y, Aoki M
Mol Clin Oncol 21 ( 3 ) 62 - 62 2024.9
-
Additive antitumor effect of arsenic trioxide with exposure to ionizing radiation to human acute promyelocytic leukemia HL‑60 cells.
Morino Y, Sugiyama H, Yamane K, Kikuchi M, Yamanaka T, Honda K, Monzen S
Oncol Rep 52 ( 2 ) 109 2024.8
-
Predictive serum biomarker for therapeutic resistance of HER2‑positive breast cancer patient under the postoperative adjuvant therapy
Monzen S, Tatara Y, Kikuchi M, Wojcik A et al.
BIO Clinica (Special Issue) 13 ( 1 ) 106 - 109 2024.7